Hosted on MSN14d
AbbVie and Simcere Zaiming link to develop trispecific antibodyThe humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.
NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...
(RTTNews) - AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement to advance SIM0500, an investigational drug ...
The Big Pharma is handing China’s Simcere Zaiming an undisclosed upfront payment with the potential of up to $1.05 billion in milestone payments for a phase 1-stage trispecific antibody.
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare... Enjoy extended coverage for the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback